Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:27:48.540Z.
Calculation as of: 2026-10-06T18:27:48.540Z.
Quote observation: 2026-10-06T18:25:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4ee4545eb4fe5103374f291c717036760539f0ddea1c9b76c24efb1a2679ece0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Odyssey Therapeutics, Inc.
Market Cap
$883.54M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$883.98M
EV/Sales Ratio
4.78x
TTM Avg
36.22x
3Y Avg
50.65x
5Y Avg
36.89x
Market Cap
$871.60M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$861.44M
EV/Sales Ratio
3.04x
TTM Avg
2.50x
3Y Avg
2.16x
5Y Avg
2.36x
Market Cap
$913.56M
EV/Sales Ratio
2.74x
TTM Avg
2.28x
3Y Avg
2.71x
5Y Avg
2.71x
Market Cap
$849.66M
EV/Sales Ratio
1.42x
TTM Avg
1.51x
3Y Avg
1.76x
5Y Avg
1.99x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $883.54M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $883.98M | 4.78x | 36.22x | 50.65x | 36.89x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $871.60M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $898.66M | 1.95x | 1.63x | 1.56x | 1.52x |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $861.44M | 3.04x | 2.50x | 2.16x | 2.36x |
| SI-BONE, Inc. (SIBN)vs › | $856.68M | 3.89x | 3.51x | 4.09x | 5.12x |
| SL Science Holding Ltd (SLBT)vs › | $855.16M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $913.56M | 2.74x | 2.28x | 2.71x | 2.71x |
| QuidelOrtho Corporation (QDEL)vs › | $849.66M | 1.42x | 1.51x | 1.76x | 1.99x |
| Pacific Biosciences of California, Inc. (PACB)vs › | $844.84M | 9.35x | 7.35x | 8.21x | 14.47x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
